p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors

Triple-negative breast cancers (TNBCs) lack effective targeted therapies, and cytotoxic chemotherapies remain the standard of care for this subtype. Owing to their increased genomic instability, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are being tested against TNBCs. In particular, cli...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Eduardo Cepeda Cañedo, Stephanie Totten, Ryuhjin Ahn, Paul Savage, Deanna MacNeil, Jesse Hudson, Chantal Autexier, Genevieve Deblois, Morag Park, Michael Witcher, Josie Ursini-Siegel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Clinical investigation 2021-02-01
Colecção:	JCI Insight
Assuntos:	Cell biology Oncology
Acesso em linha:	https://doi.org/10.1172/jci.insight.138382
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!